Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?
Executive Summary
Brand and generic industries are on opposite sides of spectrum on most issues; there is mutual opposition, however, to the use of a meaningless four-letter suffix in the proper name of a product.
You may also be interested in...
Biosimilar Labeling: US FDA’s Final Guidance Means Status Quo For Sponsors
Advice document, little changed from a March 2016 draft, continues to reflect agency’s view that clinical studies supporting a demonstration of biosimilarity should not be included in labeling.
Biosimilar Labeling: US FDA’s Final Guidance Means Status Quo For Sponsors
Advice document, little changed from a March 2016 draft, continues to reflect agency’s view that clinical studies supporting a demonstration of biosimilarity should not be included in labeling.
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Draft guidelines on interchangeability and statistical considerations due by end of 2017, suggesting long-awaited documents may not see the light of day this year as many had hoped.